Rare MEFV variants are not associated with risk to develop multiple sclerosis and severity of disease

Abstract

Background:

Recent studies suggest an association between rare variants in Mediterranean fever (MEFV), the gene underlying the auto-inflammatory disorder Familial Mediterranean Fever (FMF), the risk to develop multiple sclerosis (MS) and severity of MS.

Objective:

The objective of this study is to investigate these findings in a Belgian MS population and to test for association with additional clinical parameters such as treatment response.

Methods:

MEFV was sequenced in a cohort of MS patients (N=94) suffering from auto-inflammatory symptoms, systemic side-effects upon interferon-beta (IFN-β) treatment, or patients in whom glatiramer acetate was started as first choice due to severe fatigue. Five rare non-synonymous variants were detected in this cohort and subsequently genotyped in 915 MS patients and 763 healthy controls.

Results:

We observed no association between these alleles and susceptibility to MS (p-value=0.99) or disease severity (p-value=0.78). However, we did observe a correlation between carrying an MEFV variant and the development of systemic side-effects upon IFN-β treatment (p-value=0.022).

Conclusion:

In contrast to recent smaller studies, we did not find an association between carrying a rare variant in the MEFV gene and the risk to develop MS or disease severity. However, carrying rare variants in MEFV was associated with the development of severe systemic side-effects upon IFN-β treatment.

Keywords

Multiple sclerosis genetics IFN-β immunology

Get full access to this article

View all access options for this article.

References

Compston

Coles

. Multiple sclerosis. Lancet 2008; 372: 1502–1517.

Oksenberg

Baranzini

. Multiple sclerosis genetics – is the glass half full, or half empty? Nat Rev Neurol 2010; 6: 429–437.

The International Multiple Sclerosis Genetics Consortium & The Wellcome Trust Case Control Consortium 2. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 2011; 476: 214–219.

Manolio

Collins

Cox

. Finding the missing heritability of complex diseases. Nature 2009; 461: 747–753.

Akman-Demir

Gul

Gurol

. Inflammatory/demyelinating central nervous system involvement in familial Mediterranean fever (FMF): Coincidence or association? J Neurol 2006; 253: 928–934.

Kumpfel

Hoffmann

Rubsamen

. Late-onset tumor necrosis factor receptor-associated periodic syndrome in multiple sclerosis patients carrying the TNFRSF1A R92Q mutation. Arthritis Rheum 2007; 56: 2774–2783.

Yahalom

Kivity

Lidar

. Familial Mediterranean fever (FMF) and multiple sclerosis: An association study in one of the world's largest FMF cohorts. Eur J Neurol 2011; 18: 1146–1150.

Kumpfel

Hoffmann

Pellkofer

. Multiple sclerosis and the TNFRSF1A R92Q mutation: Clinical characteristics of 21 cases. Neurology 2008; 71: 1812–1820.

De Jager

Jia

Wang

. Meta-analysis of genome scans and replication identify CD6, IRF8 and TNFRSF1A as new multiple sclerosis susceptibility loci. Nat Genet 2009; 41: 776–782.

10.

Goris

Fockaert

Cosemans

. TNFRSF1A coding variants in multiple sclerosis. J Neuroimmunol 2011; 235: 110–112.

11.

Yucesan

Canyigit

Turkcapar

. The coexistence of familial Mediterranean fever with multiple sclerosis. Eur J Neurol 2004; 11: 716–717.

12.

Ugurlu

Bolayir

Candan

. Familial mediterranean fever and multiple sclerosis – a case report. Acta Reumatol Port 2009; 34: 117–119.

13.

French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997; 17: 25–31.

14.

Kilim

Magal

Shohat

. Expanding the panel of MEFV mutations for routine testing of patients with a clinical diagnosis of familial Mediterranean fever. Isr Med Assoc J 2011; 13: 206–208.

15.

Ben-Chetrit

Touitou

. Familial mediterranean Fever in the world. Arthritis Rheum 2009; 61: 1447–1453.

16.

Gershoni-Baruch

Shinawi

Leah

. Familial Mediterranean fever: Prevalence, penetrance and genetic drift. Eur J Hum Genet 2001; 9: 634–637.

17.

Ben-Chetrit

Peleg

Aamar

. The spectrum of MEFV clinical presentations – is it familial Mediterranean fever only? Rheumatology (Oxford) 2009; 48: 1455–1459.

18.

Booty

Chae

Masters

. Familial Mediterranean fever with a single MEFV mutation: Where is the second hit? Arthritis Rheum 2009; 60: 1851–1861.

19.

Unal

Dursun

Emre

. Evaluation of common mutations in the Mediterranean fever gene in multiple sclerosis patients: Is it a susceptibility gene? J Neurol Sci 2010; 294: 38–42.

20.

Kümpfel

Gerdes

Wacker

. Familial Mediterranean fever-associated mutation pyrin E148Q as a potential risk factor for multiple sclerosis. Mult Scler 2012; 18: 1229–1238.

21.

Shinar

Livneh

Villa

. Common mutations in the familial Mediterranean fever gene associate with rapid progression to disability in non-Ashkenazi Jewish multiple sclerosis patients. Genes Immun 2003; 4: 197–203.

22.

Poser

Paty

Scheinberg

. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols. Ann Neurol 1983; 13: 227–231.

23.

McDonald

Compston

Edan

. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121–127.

24.

Roxburgh

Seaman

Masterman

. Multiple Sclerosis Severity Score: Using disability and disease duration to rate disease severity. Neurology 2005; 64: 1144–1151.

25.

Purcell

Neale

Todd-Brown

. PLINK: A tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 2007; 81: 559–575.

26.

Touitou

. The spectrum of Familial Mediterranean Fever (FMF) mutations. Eur J Hum Genet 2001; 9: 473–483.

27.

Ryan

Masters

Booty

. Clinical features and functional significance of the P369S/R408Q variant in pyrin, the familial Mediterranean fever protein. Ann Rheum Dis 2010; 69: 1383–1388.

28.

Centola

Wood

Frucht

. The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. Blood 2000; 95: 3223–3231.

29.

Ben-Sasson

Hu-Li

Quiel

. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation. Proc Natl Acad Sci U S A 2009; 106: 7119–7124.

30.

Gabay

Lamacchia

Palmer

. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6: 232–241.

31.

Lachmann

Sengul

Yavuzsen

. Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. Rheumatology (Oxford) 2006; 45: 746–750.

32.

Gris

Iocca

. NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses. J Immunol 2010; 185: 974–981.

33.

Jha

Srivastava

Brickey

. The inflammasome sensor, NLRP3, regulates CNS inflammation and demyelination via caspase-1 and interleukin-18. J Neurosci 2010; 30: 15811–15820.

34.

Cortes

Brown

. Promise and pitfalls of the Immunochip. Arthritis Res Ther 2011; 13(1): 101.